222 related articles for article (PubMed ID: 32564268)
1. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.
Zubiaur P; Saiz-Rodríguez M; Ochoa D; Navares-Gómez M; Mejía G; Román M; Koller D; Soria-Chacartegui P; Almenara S; Abad-Santos F
Adv Ther; 2020 Aug; 37(8):3537-3550. PubMed ID: 32564268
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.
Gouin-Thibault I; Delavenne X; Blanchard A; Siguret V; Salem JE; Narjoz C; Gaussem P; Beaune P; Funck-Brentano C; Azizi M; Mismetti P; Loriot MA
J Thromb Haemost; 2017 Feb; 15(2):273-283. PubMed ID: 27893182
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
4. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
Sychev D; Skripka A; Ryzhikova K; Bochkov P; Shevchenko R; Krupenin P; Ivashchenko D; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134727
[TBL] [Abstract][Full Text] [Related]
5. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
Ji Q; Zhang C; Xu Q; Wang Z; Li X; Lv Q
Br J Clin Pharmacol; 2021 May; 87(5):2247-2255. PubMed ID: 33179295
[TBL] [Abstract][Full Text] [Related]
6. The Distribution of the Genotypes of
Abdrakhmanov A; Akilzhanova A; Shaimerdinova A; Zhalbinova M; Tuyakova G; Abildinova S; Albayev R; Ainabekova B; Chinybayeva A; Suleimen Z; Bekbossynova M
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372371
[TBL] [Abstract][Full Text] [Related]
7. Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism.
Mejía-Abril G; Zubiaur P; Navares-Gómez M; Villapalos-García G; Román M; Ochoa D; Abad-Santos F
Front Pharmacol; 2021; 12():660639. PubMed ID: 33995083
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of dabigatran etexilate interindividual variability.
Dimatteo C; D'Andrea G; Vecchione G; Paoletti O; Cappucci F; Tiscia GL; Buono M; Grandone E; Testa S; Margaglione M
Thromb Res; 2016 Aug; 144():1-5. PubMed ID: 27261537
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
10. Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report.
Wu T; Xia X; Fu J; Chen W; Zhang J
Medicine (Baltimore); 2020 Sep; 99(36):e22084. PubMed ID: 32899083
[TBL] [Abstract][Full Text] [Related]
11. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Karaca RO; Kalkisim S; Altinbas A; Kilincalp S; Yuksel I; Goktas MT; Yasar U; Bozkurt A; Babaoglu MO
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):199-206. PubMed ID: 27611887
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects.
Saiz-Rodríguez M; Ochoa D; Herrador C; Belmonte C; Román M; Alday E; Koller D; Zubiaur P; Mejía G; Hernández-Martínez M; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):321-329. PubMed ID: 30281924
[TBL] [Abstract][Full Text] [Related]
14. The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation.
Zhu Z; Qian C; Su C; Tao H; Mao J; Guo Z; Zhu X; Pan J
BMC Cardiovasc Disord; 2022 Nov; 22(1):481. PubMed ID: 36368930
[TBL] [Abstract][Full Text] [Related]
15. Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects.
Pena MÁ; Muriel J; Saiz-Rodríguez M; Borobia AM; Abad-Santos F; Frías J; Peiró AM
Clin Drug Investig; 2020 Jul; 40(7):617-628. PubMed ID: 32415468
[TBL] [Abstract][Full Text] [Related]
16. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.
Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Koller D; Talegón M; Ovejero-Benito MC; López-Rodríguez R; Cabaleiro T; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):501-511. PubMed ID: 29136336
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
19. The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects.
Liu Y; Yang C; Qi W; Pei Z; Xue W; Zhu H; Dong M; Guo Y; Cong D; Wang F
Pharmgenomics Pers Med; 2021; 14():477-485. PubMed ID: 33935512
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
